New psoriasis cream takes on old standby in Head-to-Head trial

NCT ID NCT07635043

Not yet recruiting Disease control Sponsor: Pakistan Institute of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether a newer cream called tapinarof works better than the standard betamethasone cream for mild-to-moderate plaque psoriasis. About 120 adults will use one of the two creams daily for up to 12 weeks. The main goal is to see how many people get at least a 75% improvement in their psoriasis symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tapinarof cream 1% and betamethasone dipropionate 0.05% cream
What this could lead to: If tapinarof works as well or better than betamethasone, it could offer a new topical treatment option for mild-to-moderate plaque psoriasis.
What could go wrong: This is a small, early-phase trial (120 people) that hasn't started yet. Results may not apply to everyone, and tapinarof might not prove superior or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS (PSO) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS (PSO)

Contacts and locations

Show contact details

Locations

Pakistan institute of medical sciences(PIMS)

Islamabad, Federal, 44000, Pakistan

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.